New drug shows promise for rare gut and lung tumors

NCT ID NCT07272512

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing an oral drug called surufatinib in 350 adults with advanced neuroendocrine tumors (NETs). The drug works by cutting off blood supply to tumors and boosting the immune system. Researchers want to see if it helps control the disease and improves survival in real-world settings, not just in strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Surufatinib (an oral drug that targets blood vessel growth and immune signals)
What this could lead to: If successful, this study could confirm surufatinib as a standard treatment option to slow tumor growth and extend survival for people with advanced neuroendocrine tumors.
What could go wrong: This is a single-arm, real-world study without a comparison group, so results may be less definitive. Side effects like high blood pressure, fatigue, or liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE NEOPLASMS NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Huadong Hospital Affiliated to Fudan University
RECRUITING

Shanghai, China
Huashan Hospital Affiliated to Fudan University
RECRUITING

Shanghai, China
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, China
Shanghai General Hospital shanghai jiao tong university school of medicine
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.